Merck KGaA
CompanyGermanyROR
Merck KGaA develops 3 assets, the furthest approved (metformin in type 2 diabetes). Mostly small molecule and supplement acting on Mitochondrial biogenesis (PGC-1α), AMPK signalling and Insulin/IGF-1 signalling; based in Germany.
- Assets
- 3
- Furthest
- Approved
- Trials
- 30
- Signals
- 1
Pipeline
3Activates AMPK and reduces hepatic gluconeogenesis
ApprovedSmall moleculeMitochondrial biogenesis (PGC-1α)AMPK signallingtype 2 diabetesaging (Phase 3)
Vitamin D receptor agonist regulating calcium absorption and bone mineralization.
Phase 3SupplementVDRosteoporosisosteoporosis postmenopausal
Phase 1Small moleculesolid tumor
Full company profiles: pipeline, trials, funding and people.
See Pro- Evidence behind the mechanisms10
- Trials52
- Signals7
- Similar companies6
Updated 7 Oct 2026 · 100 sources